The FDA Just Scheduled the Most Consequential Peptide Meeting in Years

The FDA peptide reclassification process took its most significant step forward on Tuesday.

On Tuesday, the FDA announced it will convene the Pharmacy Compounding Advisory Committee on July 23 and 24 to decide whether seven peptides should return to the Category 1 bulk drug substances list—the list that determines whether compounding pharmacies can legally prepare them. A second meeting, covering five additional peptides, will happen before February 2027. (FDA announcement via STAT News)

This is the FDA peptide reclassification meeting the peptide community has been waiting for since February, when HHS Secretary Robert F. Kennedy Jr. announced on Joe Rogan’s podcast that he intended to reclassify approximately 14 of the 19 peptides the FDA placed on its Category 2 restricted list in 2023. (Washington Post)

That February announcement generated enormous excitement. It also generated a problem: as of today—nearly two months later—the FDA has not published a formal update to the Category 1 list. Kennedy said the words. the regulatory machinery behind FDA peptide reclassification has not yet moved. What we got today is the first concrete evidence that the machinery is starting to turn. The FDA peptide reclassification timeline is now real.

What the FDA Peptide Reclassification Actually Involves

In 2023, the FDA removed 19 peptides from the list of substances that 503A and 503B compounding pharmacies could legally use. The practical effect was immediate: compounds like BPC-157, TB-500, and AOD-9604 went from “your doctor can prescribe it and a compounding pharmacy can make it” to “legally, nobody can compound this.” The gray market, of course, didn’t get the memo—but the legitimate compounding pathway was shut down.

The July meeting will review seven of those 19 peptides. The FDA hasn’t named which seven, but based on the reclassification trajectory and prior PCAC referrals, the likely candidates include compounds used for wound healing, obesity, insomnia, and immune modulation. Five peptides—CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank—were already referred to the PCAC for review in September 2024, so those are near-certainties for the July agenda. (UPI)

The second meeting, before February 2027, will cover the remaining five.

What “Category 1” Actually Means

This is where the coverage gets sloppy, and where Peptidings needs to be precise.

Reclassification to Category 1 means a compounding pharmacy can legally prepare the compound under a physician’s prescription. It does not mean:

• The peptide is FDA-approved
• The peptide has been evaluated for safety in controlled trials
• The peptide meets the same manufacturing standards as an FDA-approved drug
• You can buy it over the counter

Category 1 is permission to compound, not an endorsement of efficacy. Understanding what FDA peptide reclassification does—and doesn’t—mean matters. The distinction matters enormously, and most of the mainstream coverage—NBC, CBS, CNN—has blurred it. (NBC News; CBS News)

The Pharmaceutical-Grade Problem

There’s a practical complication that almost nobody is talking about. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, told reporters that for many of these peptides, “it is my understanding that there is no pharmaceutical-grade active ingredient available.” (Washington Post)

Federal law requires compounded drugs to use pharmaceutical-grade source material. If no pharmaceutical-grade BPC-157 exists—and to our knowledge, none does—then reclassifying it to Category 1 creates a legal permission that no legitimate pharmacy can actually use. The compound would be theoretically compoundable but practically unavailable through legitimate channels.

This is not a small detail. It’s the gap between the headline and the reality, and it’s the gap where the gray market thrives.

STAT’s Read on the Panel

STAT News reports that the advisory panel members are “expected to support” Kennedy’s reclassification push. (STAT News) If that’s accurate, the July meeting may be less of a debate and more of a ratification—which would mean Category 1 status for the first batch of peptides could happen before the end of summer.

That would be the most significant regulatory shift in the peptide space since the 2023 restrictions. It would affect how we write about legal status, sourcing, and access in every compound article we cover.

What Peptidings Is Watching

Three things:

Which seven peptides make the July agenda. The FDA hasn’t published the specific list. When it does, we’ll update every affected compound article’s legal status and sourcing section within 24 hours.

Whether pharmaceutical-grade supply materializes. Reclassification without pharmaceutical-grade source material is a theoretical win. We’ll track whether any USP-grade manufacturers step up to fill the gap.

Whether the panel’s recommendation becomes final agency action. Advisory panels recommend. The FDA decides. Those are not the same thing, and the timeline between recommendation and publication of a revised Category 1 list is unclear.

We’ll cover each of these as the FDA peptide reclassification process develops. In the meantime, the current legal status of every peptide on our site reflects what the FDA has actually done—not what anyone has said they intend to do.

For compound-level evidence reviews, see our articles on BPC-157, TB-500, AOD-9604, Selank, and Ipamorelin. Each includes current FDA and WADA regulatory status.

Peptidings tracks the regulatory, scientific, and clinical landscape for 130+ peptide compounds. Every compound article includes current FDA and WADA status. For the full evidence review on any compound mentioned above, visit the Research Library.